ResearchDx Partners with Lucid Diagnostics for First DNA Methylation Test for Barrett’s Esophagus

As Lucid Diagnostics’ commercial diagnostic laboratory partner, the new EsoGuard esophageal DNA laboratory-developed test (LDT) was developed and completed CLIA and CAP certification at ResearchDx’s premier molecular laboratory, PacificDx. The first of its kind, this non-invasive DNA test was designed to detect the presence of dysplastic and non-dysplastic Barrett’s Esophagus (BE) and esophageal adenocarcinoma (EAC) […]

Read More

Negative Gluten ID Test Results can ‘Rule Out’ Celiac Disease in High Risk Populations

Brief:  First degree relatives of individuals with celiac disease are at elevated risk for developing a similarly severe gluten intolerance disorder. However, a quick screening test for the genetic alterations responsible for encoding gluten recognition immune receptors can rule out celiac disease risk in these individuals. Developed by Targeted Genomics, the DNA-based, non-invasive Gluten ID […]

Read More

Molecular Medicine Tri-Con Meeting

Irvine, CA — Jan 28, 2020 — ResearchDx will attend the Molecular Medicine Tri-Con Meeting in San Francisco California, March 1–4. Please visit our booth #600, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show. 

Read More

Blood-Based Biomarkers Discriminate IBS from IBD with High Degree of Certainty in Patients with Chronic Diarrhea

Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — July 18, 2019 — ResearchDx will attend the Association of Molecular Pathology (AMP) in Baltimore, Maryland November 7–9, 2019. Please visit our booth #2967, or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.    

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — Oct 1, 2018 — ResearchDx will attend the Association of Molecular Pathology (AMP) in San Antonio, Texas, November 1–3, 2018. Please visit booth #602, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show.

Read More

Association for Molecular Pathology (AMP)

Irvine, CA — November 7, 2017 — ResearchDx will be at the Association for Molecular Pathology (AMP) in Salt Lake City, Utah, November 16-18, 2017. Please visit us at booth 608 or call us at 866.225.9195 or 949.812.6902 to set up a consultation at the show.

Read More

ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers

Irvine, CA—October 2, 2017—ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and […]

Read More

Finding Needles in the Tumor Haystack: Single Cell HER2 Testing with DEPArray™ NxT Technology

Inside the heterogeneous tumor tissue samples sent to clinical pathology laboratories for HER2 gene testing are cancer genomes with their own inherent complexity. The biopsy (or surgical excision) tissue represents a mixture of genomes from the tumor and normal stroma. Further compounding the heterogeneity problem, tumor genomes harboring HER2 gene amplifications may have amplified HER2 […]

Read More